Spyre Therapeutics, Inc. announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective prior to market open on Monday, December 23, 2024. The NBI tracks the performance of biotechnology and pharmaceutical securities listed on The Nasdaq Stock Market.
Inclusion in the NBI requires companies to meet specific eligibility criteria, including minimum market capitalization, average daily trading volume, and seasoning as a public company. This addition can enhance Spyre's visibility within the biotechnology sector.
The Nasdaq Biotechnology Index is evaluated annually in December and is calculated under a modified capitalization-weighted methodology. This development may lead to increased institutional interest and trading liquidity for Spyre's common stock.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.